Sunday, September 14th, 2025

SSG Expands Property Portfolio with S$50.2 Million Acquisition of Commercial Properties from DFI

Date of Report: September 30, 2024
Broker Name: CGS International Securities


Acquisition of Commercial Properties from DFI
SSG has made a strategic acquisition of two commercial properties located in Singapore. These properties, situated in Siglap and Toa Payoh, were purchased from DFI for a total consideration of S$50.2 million. This acquisition highlights SSG’s focus on expanding its property portfolio within Singapore’s commercial real estate sector.


Strategic Importance of the Acquisition
The acquisition of these commercial properties aligns with SSG’s broader business strategy to strengthen its presence in Singapore’s real estate market. By adding these key properties to its portfolio, SSG aims to leverage the growth potential in commercial real estate, which can offer stable income streams and enhance its overall asset base.


This detailed summary from the September 30, 2024, report outlines SSG’s acquisition of commercial properties from DFI and its strategic implications for the company’s real estate portfolio.

SATS Ltd: Tempered Volume Growth Assumptions Amid Global Economic Uncertainty

SATS Ltd: Tempered Growth Expectations Amidst Global Headwinds CGS International | April 10, 2025 Uncertain Macroeconomic Outlook Dents SATS’s Growth Prospects SATS Ltd, a leading provider of aviation services, faces a challenging period ahead...

WCT Holdings Unveils Paradigm REIT to Strengthen Balance Sheet and Boost Growth

Date: September 19, 2024Broker Name: CGS International Securities Malaysia Sdn. Bhd. Shariah Compliance and ESG Score Shariah Compliance: WCT Holdings is identified as Shariah-compliant, which may appeal to certain institutional and individual investors. ESG...

Hansoh Pharmaceutical (3692 HK) 2025 Outlook: High Double-Digit Growth, Strong Earnings & Raised Target Price to HK$50

UOB Kay Hian Date of Report: Tuesday, 19 August 2025 Hansoh Pharmaceutical Group Delivers Strong 1H25 Results and Raises 2025 Revenue Guidance Executive Summary Hansoh Pharmaceutical Group, a leading R&D-driven pharmaceutical company in China,...